PetIQ's Muscle Play: A Calculated Bet on Pet Longevity and Wellness

EAGLE, Idaho – July 29, 2026 – PetIQ's announcement today that it has acquired MYOS Corp is far more than a routine corporate consolidation. On the surface, it’s a straightforward expansion, bringing MYOS’s unique muscle health products under the umbrella of a pet wellness giant. But look closer, and the deal reveals a sophisticated strategic pivot, a calculated bet on the powerful economic and societal forces reshaping the multi-billion-dollar pet care industry. Backed by the deep pockets and brand-building acumen of private equity firm Bansk Group, PetIQ is not just buying a product line; it is acquiring a scientifically validated foothold in the next frontier of pet care: proactive longevity.

This move signals a definitive shift away from a market historically dominated by reactive treatments and basic needs. Instead, it places PetIQ at the forefront of a movement driven by the profound humanization of pets, where owners now act as discerning healthcare advocates for their animal companions, demanding the same level of scientific rigor and preventive care they expect for themselves.

A Strategic Play in a Booming Market

The underlying economics of this deal are rooted in the explosive growth of the pet wellness sector. The global pet supplement market, valued at over $630 million in 2022, is on a trajectory to exceed $1 billion by 2030. Within this space, the mobility and joint health segment has long been the dominant category, but the acquisition of MYOS allows PetIQ to carve out and lead a more specialized, high-value niche: muscle health and preservation.

This is a savvy move in a market where differentiation is key. While competitors crowd the shelves with glucosamine and chondroitin for joint support, PetIQ now gains a proprietary, patented ingredient in Fortetropin®. This allows the company to address a crucial, often-overlooked aspect of aging and mobility. As pets live longer, muscle atrophy (sarcopenia) becomes as significant a challenge as joint degradation. By targeting muscle health, PetIQ can offer a more holistic solution for vitality in aging, injured, or highly active pets.

The acquisition is a clear manifestation of the strategy set in motion when Bansk Group took PetIQ private in a $1.5 billion transaction in late 2024. Bansk’s playbook focuses on identifying distinctive consumer brands and fueling their growth through strategic investments and acquisitions. With this deal, Bansk and PetIQ are capitalizing on the premiumization of pet care, where owners are increasingly willing to pay for products with demonstrable, science-backed benefits.

"Pet parents are increasingly looking for solutions that support their pets' mobility, recovery, and long-term vitality — not just treatment after a problem arises," said Camillo Pane, CEO of PetIQ. His statement underscores the company’s focus on the fast-growing preventive health category, a segment less susceptible to economic downturns due to the non-discretionary nature of spending on beloved pets.

The Science of Strength: Fortetropin's Clinical Edge

At the heart of the acquisition is Fortetropin®, a proprietary bioactive compound derived from fertilized egg yolk. What makes it a standout asset is its mechanism of action and the clinical data supporting it. Fortetropin® works by modulating myostatin, a natural protein that acts as the body's own regulator to inhibit muscle growth. By managing myostatin, the ingredient helps preserve existing muscle mass and support the growth of new tissue.

This is not just marketing theory; it's backed by a portfolio of over a dozen clinical studies in both humans and animals. One key study in dogs recovering from TPLO surgery—a common orthopedic procedure—found that dogs receiving Fortetropin® did not experience the significant muscle loss and spike in serum myostatin levels seen in the placebo group. This provides compelling evidence for its use in post-surgical recovery and mitigating disuse atrophy. Further research has pointed to its ability to influence key biological pathways, upregulating those that promote muscle synthesis (mTOR) and downregulating those that cause muscle breakdown (Ubiquitin).

By acquiring a company with this level of scientific validation, PetIQ elevates its entire wellness portfolio. It gains a powerful new narrative that appeals directly to the modern, research-savvy consumer and the influential veterinary community. The plan to keep the MYOS and Fortetropin® brand names intact is a testament to the brand equity MYOS has already built on its scientific foundation.

The Evolving Demands of Modern Pet Parenthood

This acquisition is a direct response to a fundamental societal shift. The modern pet owner's relationship with their animal is no longer one of simple ownership but of parenthood. This “humanization” trend is the primary engine driving the premiumization of the entire pet industry. Owners who track their own biometrics with wearables and seek out functional foods are now applying the same wellness-oriented mindset to their pets.

They are no longer satisfied with just flea and tick prevention or basic nutrition. They are actively seeking solutions for anxiety, gut health, cognitive function, and, crucially, healthy aging. The demand is for products that don't just extend lifespan, but healthspan—the period of life spent in good health. Muscle health is central to this, as mobility is a primary indicator of an older pet's quality of life.

PetIQ is positioning itself to meet this sophisticated demand head-on. The company’s vast distribution network, which spans major retailers, e-commerce platforms, and a network of over 2,600 community clinics and wellness centers, provides the perfect infrastructure to scale MYOS's specialized products. For MYOS, this partnership is transformative. As its CEO, Joe Mannello, noted, "PetIQ's distribution reach, brand-building expertise, and operating discipline are exactly what MYOS and Fortetropin® need to realize their full potential."

By integrating a clinically proven, specialized product into its mass-market distribution machine, PetIQ is making advanced wellness solutions more accessible. This move bridges the gap between niche, vet-recommended products and the broad consumer market, effectively shaping the future of over-the-counter pet wellness and solidifying PetIQ's role as a dominant force within it.